4.70Open4.70Pre Close0 Volume10 Open Interest7.50Strike Price0.00Turnover641.01%IV-14.29%PremiumDec 20, 2024Expiry Date5.05Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4066Delta0.0909Gamma0.41Leverage Ratio-0.0304Theta-0.0038Rho-0.17Eff Leverage0.0026Vega
Cardiff Oncology Stock Discussion
Cardiff Oncology Inc: Announces New Patent With Claims for Use of Onvansertib in Treating Kras Mutated Mcrc
loading...
loading...
Risk Assessment
CRDF is assessed as a high-risk investment with a risk level score of 8/10. This elevated risk stems from the company's negative financial position, large operating losses, and heavy reliance on equity financing, which could lead to volatility and rapid changes in stock price. The Biotechnology sector's low appeal further contributes to the stock's risk, limiting investor interest. Short interest is high, suggesting a significant portion of investors ...
In a significant development that has caught the attention of investors, Cardiff Oncology Inc. (NASDAQ: CRDF) saw an impressive 24% surge in their stock price yesterday, closing at $3.58. This sudden upswing comes amidst positive sentiments from leading investment banking and institutional securities firm, Piper Sandler, which has set a bullish price target of ...
🤘🏻
No comment yet